Novo Nordisk A/S left open the door for additional work on its pill version of Ozempic for Alzheimer’s disease after a pair ...

Novo Nordisk says it still thinks GLP-1 drugs could be a promising treatment for Alzheimer’s, despite two disappointing ...

While Eli Lilly stock has surged beyond a $1 trillion market capitalization, Novo Nordisk is having difficulty keeping up, ...

An oral version of semaglutide, the active ingredient in blockbuster drugs Ozempic and Wegovy, failed to slow the progression ...

The maker of the weight loss and diabetes drugs Wegovy and Ozempic has cut the prices for most versions of the blockbuster ...

Eli Lilly announced trial results for its weight-loss medication, orforglipron, in August. Orforglipron is a once-daily oral ...

The US government said Tuesday it negotiated a 71% discount off of the list price of Novo Nordisk A/S’s blockbuster drugs ...

Eli Lilly and Novo Nordisk have announced they are working on new oral drugs that can be used for type-2 diabetes and weight loss.

Four patients who developed a serious eye disease after using Novo Nordisk A/S’s blockbuster weight-loss drugs have been granted compensation in Denmark, the drugmaker’s home market.

A new study reported that Novo Nordisk spent $7.5 million over 2 years on more than 15,000 internet keywords — many focused ...

This follows recent successful efforts by the Trump administration to cut the price of this compound for certain patients.

In the early November announcement of its agreement with the government, Lilly pledged to reduce the self-pay price of ...